REVBHealthcare · BiotechnologyThe 1 Wall Street analysts covering Revelation Biosciences, Inc. hold a median 12-month price target of $124 — +2917.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 11 of 100 as at 4 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Revelation Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (98): Smaller than most of the companies we track.
Value (5): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on REVB, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +2917.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Feb 2023 | Roth MKM | Maintains | Buy | $5.00 → $15 |
| 17 Feb 2022 | Roth Capital | Initiates | Buy | $12 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
REVB appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 73% of US stocks
Cheaper than 88% of US stocks
Cheaper than 59% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 9% of US stocks
Higher than 4% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Revelation Biosciences, Inc. has a market value of $2.5M and an enterprise value of −$8.4M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$10.8M.
Diluted earnings per share, trailing twelve months: $−12.31.
Free cash flow in the twelve months to 30 June 2026: −$9.4M.
Trailing P/E: 0.1×; forward P/E: −0.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Revelation Biosciences, Inc. employs 8 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Revelation Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Revelation Biosciences announced it will implement a 1-for-7 reverse split of its common stock on October 20, 2026. The shares will begin trading on a post-split basis at the start of trading that morning.
Why it matters — REVB watchers may note the upcoming change to the share structure and the date trading will reflect the reverse split.
Revelation Biosciences announced it has selected Avance Clinical, a full-service contract research organization with global operations, as the CRO for its Phase 2/3 adaptive-design TITAN study evaluating Gemini in patients with acute kidney injury.
Why it matters — REVB watchers would care because selecting a CRO is a key step toward advancing the TITAN study, a major clinical milestone for the company's Gemini candidate.
Revelation Biosciences reported financial results for the three and six months ended June 30, 2026, and highlighted progress on its Phase 2/3 clinical trial for Gemini in acute kidney injury, including the formation of an Acute Kidney Injury Advisory Board and startup activities.
Why it matters — A REVB watcher would care because the company is advancing its pivotal Phase 2/3 study for Gemini, which an independent market assessment suggested addresses a $94 billion total addressable market.
Revelation Biosciences announced results of an independent market assessment identifying a potential $94 billion total addressable market for Gemini in treating Stage 2 and Stage 3 Acute Kidney Injury, confirming an unmet medical need. The assessment noted that AKI affects more than 10% of hospitalized patients and more than 50% of intensive care unit patients, per publicly available data.
Why it matters — The assessment signals a large potential commercial opportunity for Revelation's lead candidate Gemini and reinforces the size of the unmet medical need REVB is targeting.
The 1 Wall Street analysts covering Revelation Biosciences, Inc. have a median 12-month price target of $124, with estimates ranging from $112 to $137. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Revelation Biosciences, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Revelation Biosciences, Inc. 11 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Revelation Biosciences, Inc. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +2917.5% from the last close, and Ticker Nerd's factor model ranks Revelation Biosciences, Inc. 11 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Revelation Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for REVB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $112 to $137 over the next 12 months.
Revelation Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing immunologic therapies and diagnostics that modulate the innate immune system.
The most recent item we track (Business Wire, 16 Oct 2026): "Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026". Revelation Biosciences announced it will implement a 1-for-7 reverse split of its common stock on October 20, 2026. The shares will begin trading on a post-split basis at the start of trading that morning.
Revelation Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing immunologic therapies and diagnostics that modulate the innate immune system. Its current pipeline centers on product candidates designed to address inflammatory and infectious disease settings, including treatments for allergic rhinitis and chronic nasal congestion, rapid home-use diagnostics for respiratory viral infections, and intranasal immunomodulator approaches used alongside vaccination. The company also works on therapeutic programs targeting acute kidney injury, chronic kidney disease, and other conditions linked to dysregulated inflammation. Revelation Biosciences Inc. develops products intended for use in prevention and treatment across hospital, outpatient, and at-home care settings, with a focus on clinically relevant immune-response modulation. Based in San Diego, California, the company operates in the biotechnology sector and maintains a narrow, research-driven portfolio aimed at immune system therapeutics and diagnostics.
CEO Mr. James M. Rolke · 8 employees · United States · https://www.revbiosciences.com